On March 30, 2021 Flatiron Health reported that Carolyn Starrett, leader of the company’s community oncology business, will become CEO, effective April 16 (Press release, Flatiron Health, MAR 30, 2021, View Source [SID1234577372]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Starrett will succeed Co-Founder/CEO Nat Turner who, along with Co-Founder/COO Zach Weinberg, will step down from Flatiron management on April 16.
"I am honored and energized by the opportunity to lead Flatiron in our next chapter," said Starrett, who joined Flatiron in 2016. "I love Flatiron – our mission, our people, our culture. I’m excited to lead us to even greater impact on patient care and innovation in the field of real-world data, and to build a workforce that reflects the diversity of the many people who live with cancer."
Founded in 2012, Flatiron has built the leading U.S. oncology real-world data source, from which its experts aggregate, de-identify, and curate clinical, genomic, and other data modalities for research purposes. More than 280 community cancer clinics across the United States center their practices on Flatiron’s OncoCloud platform and services, and Flatiron also partners with major academic cancer centers, more than 20 top developers of oncology therapeutics, and researchers and regulators across the United States and internationally.
"It has been a privilege to help nurture the pioneering start-up born from Nat and Zach’s vision into the global leader in real-world evidence that Flatiron is today," said Severin Schwan, CEO of Roche Group, which acquired Flatiron as an independent affiliate in 2018. "Carolyn’s passion for Flatiron, her experience in technology and healthcare, and her ability to rally people around a shared vision are the perfect mix to lead Flatiron’s next life stage. I look forward to continued partnership and support."
"We conducted an extensive search and could not have been happier to realize that the right candidate was already here at home," said Turner, who will remain Chair of Flatiron’s Board of Directors. "It’s time for a new leader to take Flatiron to the next level, and I have every confidence in handing over the reins to Carolyn."